IC PHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
IC PHARMA
Largest movements
- Receivables within one year +€221,929
up €221,929 (+12.5%), from €1.8m to €2.0m
of which Trade receivables: +€195,289
- Stocks and contracts -€197,540
down €197,540 (-20.4%), from €967,590 to €770,050
- Cash -€51,857
down €51,857 (-16.2%), from €319,120 to €267,263
mainly Receivables within one year (-€221,929) and Trade debts (-€177,839)
- Short-term financial debts +€199,836
up €199,836 (+39.6%), from €504,872 to €704,707
- Trade debts -€177,839
down €177,839 (-9.6%), from €1.9m to €1.7m
- Staff costs +€24,516
up €24,516 (+12.5%), from €196,501 to €221,017
- Other operating charges +€23,867
up €23,867 (+1000.5%), from €2,386 to €26,253
- Gross operating margin +€14,703
up €14,703 (+3.5%), from €419,852 to €434,555
- Financial charges -€12,111
down €12,111 (-32.8%), from €36,914 to €24,803
- Depreciation +€7,187
up €7,187 (+60.9%), from €11,794 to €18,981
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €3,141,102 | €3,169,575 | +€28,473 | +0.9% |
| Fixed assets | 21/28 | €74,820 | €101,155 | +€26,335 | +35.2% |
| Tangible fixed assets | 22/27 | €46,213 | €72,548 | +€26,335 | +57.0% |
| Land and buildings | 22 | €668 | - | -€668 | |
| Plant, machinery and equipment | 23 | €34,323 | €45,309 | +€10,985 | +32.0% |
| Furniture and vehicles | 24 | €11,222 | €27,239 | +€16,017 | +142.7% |
| Financial fixed assets | 28 | €28,608 | €28,608 | = | 0.0% |
| Current assets | 29/58 | €3,066,282 | €3,068,420 | +€2,138 | +0.1% |
| Stocks and contracts in progress | 3 | €967,590 | €770,050 | -€197,540 | -20.4% |
| Stocks | 30/36 | €967,590 | €770,050 | -€197,540 | -20.4% |
| Amounts receivable within one year | 40/41 | €1,779,572 | €2,001,501 | +€221,929 | +12.5% |
| Trade receivables | 40 | €520,900 | €716,189 | +€195,289 | +37.5% |
| Other amounts receivable | 41 | €1,258,672 | €1,285,312 | +€26,640 | +2.1% |
| Cash at bank and in hand | 54/58 | €319,120 | €267,263 | -€51,857 | -16.2% |
| Deferred charges and accrued income | 490/1 | - | €29,606 | +€29,606 | |
| Total equity and liabilities | 10/49 | €3,141,102 | €3,169,575 | +€28,473 | +0.9% |
| Equity | 10/15 | €491,631 | €500,272 | +€8,641 | +1.8% |
| Contributions | 10/11 | €98,600 | €98,600 | = | 0.0% |
| Reserves | 13 | €40,221 | €40,221 | = | 0.0% |
| Distributable reserves | 133 | €40,221 | €40,221 | = | 0.0% |
| Profit (loss) carried forward | 14 | €352,810 | €361,451 | +€8,641 | +2.4% |
| Amounts payable | 17/49 | €2,649,472 | €2,669,303 | +€19,831 | +0.7% |
| Amounts payable within one year | 42/48 | €2,649,472 | €2,669,303 | +€19,831 | +0.7% |
| Current portion of amounts payable after more than one year | 42 | - | €11,506 | +€11,506 | |
| Financial debts | 43 | €504,872 | €704,707 | +€199,836 | +39.6% |
| Credit institutions | 430/8 | €504,872 | €704,707 | +€199,836 | +39.6% |
| Trade debts | 44 | €1,861,083 | €1,683,244 | -€177,839 | -9.6% |
| Suppliers | 440/4 | €1,861,083 | €1,683,244 | -€177,839 | -9.6% |
| Advances received on contracts in progress | 46 | €12,372 | - | -€12,372 | |
| Taxes, remuneration and social security | 45 | €19,819 | €23,402 | +€3,583 | +18.1% |
| Taxes | 450/3 | €70 | €70 | = | 0.0% |
| Remuneration and social security | 454/9 | €19,748 | €23,332 | +€3,583 | +18.1% |
| Other amounts payable | 47/48 | €251,327 | €246,444 | -€4,883 | -1.9% |
| Remuneration, social security and pensions | 62 | €196,501 | €221,017 | +€24,516 | +12.5% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €11,794 | €18,981 | +€7,187 | +60.9% |
| Other operating charges | 640/8 | €2,386 | €26,253 | +€23,867 | +1000.5% |
| Gross operating margin | 9900 | €419,852 | €434,555 | +€14,703 | +3.5% |
| Operating profit (loss) | 9901 | €209,171 | €168,304 | -€40,867 | -19.5% |
| Financial income | 75/76B | €473 | €1,623 | +€1,151 | +243.5% |
| Recurring financial income | 75 | €473 | €1,623 | +€1,151 | +243.5% |
| Financial charges | 65/66B | €36,914 | €24,803 | -€12,111 | -32.8% |
| Recurring financial charges | 65 | €36,914 | €24,803 | -€12,111 | -32.8% |
| Profit (loss) for the period before taxes | 9903 | €172,730 | €145,124 | -€27,606 | -16.0% |
| Income taxes | 67/77 | €19,063 | €16,483 | -€2,580 | -13.5% |
| Profit (loss) for the period | 9904 | €153,667 | €128,641 | -€25,026 | -16.3% |
| Profit (loss) for the period to be appropriated | 9905 | €153,667 | €128,641 | -€25,026 | -16.3% |
Source: filed annual accounts (NBB), fiscal years ended 30 June 2024 and 30 June 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 5 October 2026 via checked.be.